media – Page 375 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

COVID-19 that occurs after vaccination carries a much lower risk of severe illness

Scientists have developed several vaccines to prevent infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic. Previous studies have shown that although vaccine-induced immunity declines over time, vaccine effectiveness (VE) against severe COVID-19 persists for extended periods. Background Several studies have indicated that COVID-19 vaccines were less effective in preventing severe illness in older adults and otherwise immunocompromised patients. Nevertheless, COVID-19 vaccination has reduced disease severity among patients hospitalized due to SARS-CoV-2 infection. Fully vaccinated people who were hospitalized due to symptomatic COVID-19 were less likely to require mechanical ventilation, intensive care unit (ICU) admission, or die as compared to unvaccinated individuals. However, there remains a lack of studies that have evaluated the relationship between COVID-19 booster vaccination and disease severity using large samples infected with different SARS-CoV-2 variants. About the study A recent Journal of ...
- Source: https://www.news-medical.net/news/20230511/COVID-19-that-occurs-after-vaccination-carries-a-much-lower-risk-of-severe-illness.aspx
- 122
- May 14, 2023
AI used to build a 3D model of the Commander complex

University of Queensland researchers have used artificial intelligence to build a 3D map of key cell components to better understand dementia and infectious diseases including COVID-19. Professor Brett Collins from UQ’s Institute for Molecular Bioscience and Professor Pete Cullen from the University of Bristol led a team that modeled the 16 subunit Commander complex, a bundle of proteins that act as ‘postal workers’ in cells. Just as the postal system has processes to transport and sort cargo, cells in our bodies have molecular machines that transport and sort proteins. This protein transport system is implicated in many diseases including heart disease, Alzheimer’s disease and infections. “Knowing the 3D shape of these proteins helps us understand how they function, why mutations cause disease, and how to design drugs to target them in the future,” Professor Collins said. “Viruses such as SARS-CoV-2 – which causes COVID-19 – and human papilloma virus ...
- Source: drugdu
- 132
- May 13, 2023
Research pinpoints the time of year and hour when people have the strongest suicidal thoughts

New research has identified the month when people have the strongest suicidal thoughts, and that these thoughts occur a few months before the peak of suicide behaviors in spring/early summer. It also showed the daily peak in suicidal thought is between 4-5 a.m. Most people assume suicide rates will be highest in winter, yet spring/early summer is when suicidal behaviors peak and this finding has baffled researchers since first identified. Research from the University of Nottingham’s School of Psychology, led in collaboration with the University of Amsterdam and Harvard University, has examined the seasonal paths of suicidal thoughts and identified when suicidal thoughts peak during the year and also what time of day these thoughts are the worst. The findings have been published in Translational Psychiatry. Over a period of six years, responses were collected from over 10,000 people in the UK, US and Canada who completed questionnaires and tasks ...
- Source: drugdu
- 123
- May 13, 2023
Otsuka, Lundbeck’s Rexulti nabs new use in Alzheimer’s disease agitation

After Lundbeck and Otsuka’s Rexulti cleared a key advisory committee hurdle, the FDA has given the drug the go-ahead to treat dementia-associated agitation in Alzheimer’s disease patients With the approval, Rexulti becomes the first drug approved for this use in the United States. The FDA granted the nod based on data from two 12-week studies in which patients showered statistically significant and clinically meaningful improvements on the Cohen-Mansfield Agitation Inventory scale, according to the FDA. The metric looks at the frequency and intensity of dementia-related agitation. In the studies, Rexulti demonstrated a 31% improvement from baseline agitation symptoms compared with placebo. Agitation symptoms cover a wide group of behaviors including pacing, gesturing, profanity, shouting, and physical outbursts, Otsuka said in a release. The symptoms are the leading causes of assisted living or nursing room placement and have been known to be associated with accelerated disease progression, Tiffany Farchione, director ...
- Source: drugdu
- 111
- May 13, 2023
Sobi Emerges as Savior for CTI Biopharma Cash Crunch With $1.7B M&A Deal

CTI Biopharma has something many biotech companies aspire to achieve—revenue. Sales of its approved cancer drug are growing, but commercialization comes with costs as does development of the molecule for additional indications. CTI expects it will need to raise money, but the dismal financial conditions mean fundraising prospects for any biotech company could remain challenging for the foreseeable future. Enter Swedish Orphan Biovitrum (Sobi), the Stockholm-based rare diseases biopharmaceutical company. Sobi has agreed to acquire CTI in a cash deal that values the Seattle-based biotech at $1.7 billion. According to the terms of the deal, Sobi will pay $9.10 for each share of CTI, which represents an 89% premium to the stock’s price before the deal was announced Wednesday. The heart of the acquisition is Vonjo, a drug for myelofibrosis, a rare bone marrow cancer that impairs the production of red blood cells. Last year, the FDA granted accelerated approved ...
- Source: drugdu
- 110
- May 13, 2023
Pfizer CEO says Medicare will likely face legal action over drug price negotiations

Pfizer CEO Albert Bourla on Thursday said pharmaceutical companies will likely take legal action against Medicare drug price negotiations, which aim to cut costs for older Americans, but will likely reduce company profits. “I think that there will be legal action, but I’m not sure if we’ll be able to stop anything before 2026 or not,” Bourla said during a live-streamed interview with Reuters. Bourla referred to a provision in the Biden administration’s Inflation Reduction Act that will allow the Medicare program to negotiate prices on the costliest prescription drugs each year. The first negotiations start in September and new prices will go into effect in 2026. He said the most “certain way” to stop negotiations would be to call on Congress to introduce legislation that will revise the federal government’s plan. But Bourla noted he is “not optimistic” about that happening. Democrats control the Senate and President Joe ...
- Source: drugdu
- 115
- May 13, 2023
European Commission green lights Servier’s Tibsovo

Treatment concerns patients with IDH1-mutated acute myeloid leukaemia and IDH1-mutated cholangiocarcinoma Servier has revealed that the European Commission (EC) has approved Tibsovo – also known as ivosidenib tablets – as a therapy in two vital indications. The first is in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation. These individuals will not have been eligible to receive standard induction chemotherapy. The second is as a monotherapy among adult patients with locally advanced or metastatic cholangiocarcinoma in addition to a IDH1 R132 mutation who have previously undergone treatment using at least one prior line of systemic therapy. Tibsovo remains the only IDH1 inhibitor approved across Europe, while it has also received orphan medicine designation recognising the significant benefit brought to patients by the drug. Philippe Gonnard, executive vice president, global product strategy at Servier, explained: “IDH1 ...
- Source: drugdu
- 116
- May 13, 2023
First US cases of treatment-resistant ringworm found in patients in New York City

By Jen Christensen, CNN Could zombie fungi take over humans? Dr. Gupta explains CNN — The US Centers for Disease Control and Prevention is reporting the first known cases of an antifungal-resistant ringworm in the United States and urging providers to be on the lookout for such infections. The details of the cases were reported to the CDC in February and shared in a report published Thursday. The patients – two unrelated women in New York City – first had symptoms in 2021 and 2022. One patient had no international travel history, suggesting that there is some community spread in the US. Despite the name, ringworm is not caused by a worm; rather, it is caused by one of 40 species of fungus. In this case, the infections were caused by Trichophyton indotineae, a recently discovered fungus. Cases were first concentrated in patients in South Asia, but they’ve now also ...
- Source: drugdu
- 105
- May 13, 2023
Experiment shows thoughts influence tactile perception

If we sincerely believe that our index finger is five times bigger than it really is, our sense of touch improves. Researchers at Ruhr University Bochum demonstrated that this is the case in an experiment in which the participants were put under professional hypnosis. When the participants signaled that they understood the opposite hypnotic suggestion that their index finger was five times smaller than it actually was, their sense of touch deteriorated accordingly. The study shows that our tactile perception is affected and can be altered by our mental processes. The scientific community has been divided on this issue. Headed by PD Dr. Hubert Dinse, Professor Albert Newen and Professor Martin Tegenthoff, the researchers published their findings in the journal Scientific Reports on April 21, 2023. Two needles feel like one The researchers measured the tactile perception of their 24 test participants using the two-point discrimination method. This involves the ...
- Source: drugdu
- 105
- May 13, 2023
Mirati’s KRAS drug beats estimates in Q1, but Keytruda combo plan remains unclear

Just as Amgen’s KRAS contender Lumakras suffered a sequential sales decline, Mirati Therapeutics’ rival drug Krazati has surprised analysts in its first full quarter on the market. But investors remain more interested in Mirati’s plan for newly diagnosed lung cancer patients. After an FDA approval in KRAS-mutated non-small cell lung cancer (NSCLC) in December, Krazati generated $6.3 million in the first three months of 2023, coming in ahead of Wall Street’s expectation of $3.4 million. Krazati delivered that beat just as Lumakras’ sales in the U.S. slumped by $14 million, or 23% lower than its haul in the fourth quarter of 2022. In a sign of early interest in the therapy, Krazati has captured a third of new patient starts, Mirati’s chief commercial officer Ben Hickey told investors during a call Tuesday. Among the top 50 doctors that Mirati is targeting with its awareness efforts, 80% have prescribed Krazati, he ...
- Source: drugdu
- 369
- May 13, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.